IRIS
SACCA', FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 7.127
NA - Nord America 6.426
EU - Europa 5.033
SA - Sud America 912
AF - Africa 201
Continente sconosciuto - Info sul continente non disponibili 4
OC - Oceania 2
Totale 19.705
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.160
SG - Singapore 3.001
RU - Federazione Russa 2.258
CN - Cina 1.382
VN - Vietnam 1.326
IT - Italia 1.075
BR - Brasile 717
HK - Hong Kong 617
DE - Germania 348
NL - Olanda 291
FR - Francia 235
GB - Regno Unito 176
IN - India 155
FI - Finlandia 154
UA - Ucraina 154
CA - Canada 139
JP - Giappone 127
BD - Bangladesh 110
IE - Irlanda 102
AR - Argentina 82
KR - Corea 79
MX - Messico 79
ZA - Sudafrica 61
IQ - Iraq 48
CI - Costa d'Avorio 45
PH - Filippine 38
AT - Austria 35
PL - Polonia 35
SE - Svezia 32
ES - Italia 30
EC - Ecuador 29
TH - Thailandia 29
CO - Colombia 24
ID - Indonesia 23
TR - Turchia 22
PK - Pakistan 21
TW - Taiwan 18
EG - Egitto 17
KE - Kenya 16
LT - Lituania 15
CL - Cile 14
VE - Venezuela 14
BO - Bolivia 13
MA - Marocco 13
UZ - Uzbekistan 13
AE - Emirati Arabi Uniti 12
CZ - Repubblica Ceca 12
JO - Giordania 11
NP - Nepal 11
SA - Arabia Saudita 11
IR - Iran 10
TN - Tunisia 10
BG - Bulgaria 9
CH - Svizzera 9
DO - Repubblica Dominicana 9
MY - Malesia 9
PT - Portogallo 9
PY - Paraguay 8
BE - Belgio 7
CR - Costa Rica 7
KZ - Kazakistan 7
RS - Serbia 7
AZ - Azerbaigian 6
DZ - Algeria 6
LB - Libano 6
PE - Perù 6
RO - Romania 6
EE - Estonia 5
ET - Etiopia 5
PS - Palestinian Territory 5
AL - Albania 4
BB - Barbados 4
IL - Israele 4
JM - Giamaica 4
NI - Nicaragua 4
AM - Armenia 3
BH - Bahrain 3
GA - Gabon 3
GR - Grecia 3
KG - Kirghizistan 3
LV - Lettonia 3
MK - Macedonia 3
MU - Mauritius 3
PA - Panama 3
SY - Repubblica araba siriana 3
UY - Uruguay 3
ZW - Zimbabwe 3
AU - Australia 2
BA - Bosnia-Erzegovina 2
BN - Brunei Darussalam 2
BW - Botswana 2
BZ - Belize 2
CG - Congo 2
DK - Danimarca 2
EU - Europa 2
GF - Guiana Francese 2
GT - Guatemala 2
HN - Honduras 2
HR - Croazia 2
KW - Kuwait 2
Totale 19.657
Salva come PNG Salva come JPEG
Città #
Singapore 1.495
San Jose 1.030
Chandler 604
Hong Kong 591
Ashburn 587
Moscow 580
Beijing 395
Hefei 348
Ho Chi Minh City 343
Hanoi 296
Santa Clara 268
Amsterdam 244
Naples 187
Los Angeles 153
The Dalles 149
Lauterbourg 140
Millbury 135
Tokyo 105
Dallas 103
New York 96
Nanjing 81
Munich 80
Princeton 80
Des Moines 76
Buffalo 74
Boston 73
Napoli 73
Milan 72
São Paulo 71
Da Nang 63
Redondo Beach 63
Seoul 63
Seattle 61
Haiphong 54
Council Bluffs 49
Turku 49
Jacksonville 48
Rome 48
Lawrence 46
Orem 46
Wilmington 43
Nuremberg 41
Frankfurt am Main 40
Chicago 39
Montreal 39
Toronto 39
Cava De' Tirreni 38
Dong Ket 38
London 36
Bar Harbor 35
Nola 33
Helsinki 32
Houston 32
Norwalk 32
Warsaw 32
Denver 30
Johannesburg 30
Mexico City 30
San Francisco 27
Ottawa 26
Pune 24
Atlanta 23
Brooklyn 23
Chennai 23
Tianjin 23
Biên Hòa 22
Dearborn 21
Stockholm 21
Bollate 20
Dublin 20
Hải Dương 20
Poplar 20
Belo Horizonte 19
Nanchang 19
Phoenix 19
Baghdad 18
Can Tho 17
Manchester 16
Rio de Janeiro 16
Vienna 15
Ankara 14
Columbus 14
Curitiba 14
Querétaro 14
Redwood City 14
Thái Nguyên 14
Charlotte 13
Mumbai 13
Shenyang 13
Bangkok 12
Bến Tre 12
Changsha 12
Düsseldorf 12
Jiaxing 12
Leawood 12
Nairobi 12
Tashkent 12
Torre Annunziata 12
Washington 12
Hebei 11
Totale 10.464
Salva come PNG Salva come JPEG
Nome #
GAA-FGF14 ataxia (SCA27B): phenotypic profile, natural history progression and 4-aminopyridine treatment response 300
Insulin Sensitivity and Early-Phase Insulin Secretion in Normoglycemic Huntington's Disease Patients 224
Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study 205
A genome-wide association meta-analysis identifies a novel locus at 17q11.2 associated with sporadic amyotrophic lateral sclerosis. 203
A real-life experience with eculizumab and efgartigimod in generalized myasthenia gravis patients 194
Long-term efficacy and safety of eculizumab in Japanese patients with generalized myasthenia gravis: A subgroup analysis of the REGAIN open-label extension study 181
Epoetin alfa increases frataxin production in Friedreich's ataxia without affecting hematocrit. 176
Alterations of functional connectivity of the motor cortex in Fabry disease: An RS-fMRI study 173
Ataxia-myoclonus syndrome due to a novel homozygous ATP13A2 mutation 172
A randomized controlled pilot trial of lithium in spinocerebellar ataxia type 2. 171
Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial 169
The use of medical-grade cannabis in patients non-responders to Nabiximols 168
Modifications of resting state networks in spinocerebellar ataxia type 2 167
Vascular smooth muscle cell dysfunction in patients with migraine. 167
Cognitive impairment at diagnosis predicts 10-year multiple sclerosis progression 165
Assessment of neuroactive steroids in cerebrospinal fluid comparing acute relapse and stable disease in relapsing-remitting multiple sclerosis 165
Validation of an iPad version of the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) 162
Cognitive and functional connectivity alterations in Friedreich's ataxia 162
Benign hereditary chorea: clinical and neuroimaging features in an Italian family. 161
Cerebellum and cognition in Friedreich ataxia: a voxel-based morphometry and volumetric MRI study 159
Emotion Recognition and Psychological Comorbidity in Friedreich’s Ataxia 157
Chronic Pachymeningitis: a case of neurosyphilis with spastic paraparesis. 155
Long-term effect of epoetin alfa on clinical and biochemical markers in friedreich ataxia 155
Safety and feasibility of upper limb cardiopulmonary exercise test in Friedreich ataxia 155
‘Minimal symptom expression’ in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab 154
Ofatumumab versus Teriflunomide in Multiple Sclerosis 154
Rationale and protocol of a double-blind, randomized, placebo-controlled trial to test the efficacy, safety, and tolerability of dimethyl fumarate in Friedreich Ataxia (DMF-FA-201) 153
Multiple hormone deficiency syndrome in heart failure with preserved ejection fraction 153
Long-term therapy with miglustat and cognitive decline in the adult form of Niemann-Pick disease type C: a case report 153
Striatonigral involvement in Fabry Disease: A quantitative and volumetric Magnetic Resonance Imaging study 153
Pathological laughter as onset symptom in atypical parkinsonisms 152
Ataxia with oculomotor apraxia type 1 in southern italy: late onset and variable phenotype. 151
Long-term safety and efficacy of eculizumab in generalized myasthenia gravis 151
Post-mortem diagnosis of invasive pulmonary aspergillosis after alemtuzumab treatment for multiple sclerosis 149
The C-Terminal Cross-linked Telopeptide of Type I Collagen (CTX-I) as a Potential Cardiomyopathy Biomarker in Friedreich Ataxia Patients 148
The combined use of conventional MRI and MR spectroscopic imaging increases the diagnostic accuracy in amyotrophic lateral sclerosis. 147
Dimethyl Fumarate Mediates Nrf2-dependent Mitochondrial Biogenesis in Mice and Humans 147
Dural sinus collapsibility, idiopathic intracranial hypertension, and the pathogenesis of chronic migraine 147
Variable phenotype in a P102L Gerstmann-Straussler-Scheinker Italian family 146
Detectable interleukin-9 plasma levels are associated with impaired cardiopulmonary functional capacity and all-cause mortality in patients with chronic heart failure 146
The “crab sign”: an imaging feature of spinocerebellar ataxia type 48 146
CD4/CD8 ratio during natalizumab treatment in multiple sclerosis patients 145
Frontal defect contribution to decreasing of body mass index in Parkinson's disease patients 144
Novel mutation of SACS gene in a Spanish family with autosomal recessive spastic ataxia 144
Immunometabolic profiling of patients with multiple sclerosis identifies new biomarkers to predict disease activity during treatment with interferon beta-1a 144
Multiple hormone deficiencies in chronic heart failure 143
Predictors of survival in spinocerebellar ataxia type 2 population from Southern Italy. 143
A real-world study of alemtuzumab in a cohort of Italian patients 142
Ataxia with oculomotor apraxia type 1 in Southern Italy: late onset and variable phenotype 142
A randomized controlled clinical trial of growth hormone in amyotrophic lateral sclerosis: clinical, neuroimaging, and hormonal results. 142
Reduced intracranial volume in Fabry Disease: Evidence of abnormal neurodevelopment? 142
Longitudinal study of a cohort of MSA-C patients in South Italy: survival and clinical features 142
Cognitive trajectories in multiple sclerosis: a long-term follow-up study 142
Be aware of Wolfram syndrome when examining ataxic patients 140
Default mode network modifications in Fabry disease: A resting-state fMRI study with structural correlations 140
Anti-calcitonin gene-related peptide monoclonal antibodies for the treatment of vestibular migraine: A prospective observational cohort study 139
Very late onset in ataxia oculomotor apraxia type I. 139
Lamivudine and fingolimod co-administration in two patients with multiple sclerosis and occult hepatitis B virus infection 139
Application of the p9NORM correction method to timed neuropsychological tests in Parkinson's disease and multiple system atrophy. 139
Peripheral markers of autophagy in polyglutamine diseases 138
Adult normative values for the PATA Rate Test 138
Myocardial (123)I-metaiodobenzylguanidine scintigraphy in patients with homozygous and heterozygous parkin mutations 137
The flavor test is a sensitive tool in identifying the flavor sensorineural dysfunction in Parkinson's disease 136
Ataxia with oculomotor apraxia type 2: a clinical, pathologic, and genetic study 135
Recombinant human erythropoietin increasesfrataxin protein expression without increasing mRNA expression 135
Aprataxin 134
Stability of erythropoietin repackaging in polypropylene syringes for clinical use 133
A head-to-head observational cohort study on the efficacy and safety of monoclonal antibodies against calcitonin gene-related peptide for chronic and episodic migraine 132
A randomized trial of varenicline (Chantix) for the treatment of spinocerebellar ataxia type 3. 131
Mobitz type I and II atrioventricular blocks during fingolimod therapy 131
Degenerative and acquired sporadic adult onset ataxia 131
The complex phenotype of spinocerebellar ataxia type 48 in eight unrelated Italian families 131
Dimethyl fumarate dosing in humans increases frataxin expression: A potential therapy for Friedreich’s Ataxia 130
Predictors of Nabiximols (Sativex®) discontinuation over long-term follow-up: a real-life study 130
Eculizumab improves fatigue in refractory generalized myasthenia gravis 129
A snapshot on patient-reported outcome measures of people with multiple sclerosis on first-line therapies in a real world setting 129
Consistent improvement with eculizumab across muscle groups in myasthenia gravis 129
Variable phenotype in a P102L Gerstmann-Sträussler-Scheinker Italian family. 128
A new genetic cause of spastic ataxia: the p.Glu415Lys variant in TUBA4A 127
Efficacy of innovative therapies in myasthenia gravis: A systematic review, meta-analysis and network meta-analysis 127
A randomized clinical trial of lithium in multiple system atrophy. 127
Interplay Between Cognitive and Bowel/Bladder Function in Multiple Sclerosis 127
Bacterial and CMV pneumonia in a patient treated with alemtuzumab for multiple sclerosis 126
Autosomal recessive progressive myoclonus epilepsy with ataxia and mental retardation. 125
Metabolic Ataxias in Adults. 125
Othello syndrome in Parkinson's disease: a systematic review and report of a case series 125
Screening for dopa-responsive dystonia in patients with scans without evidence of dopaminergic deficiency (SWEDD). 124
Ocrelizumab depletes T-lymphocytes more than rituximab in multiple sclerosis 124
The EDSS integration with the Brief International Cognitive Assessment for Multiple Sclerosis and orientation tests 121
A Review of Brain and Pituitary Gland MRI Findings in Patients with Ataxia and Hypogonadism 120
Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension 120
Genetic Screening for the LRRK2 R1441C and G2019S Mutations in Parkinsonian Patients from Campania. 120
The Multiple Faces of Spinocerebellar Ataxia type 2 120
SCA Functional Index: a useful compound performance measure for spinocerebellar ataxia. 119
Olfactory function and cognition in relapsing–remitting and secondary-progressive multiple sclerosis 119
Screening for RFC-1 pathological expansion in late-onset ataxias: a contribution to the differential diagnosis. 119
Autosomal recessive progressive myoclonus epilepsy with ataxia and mental retardation. 116
Normalization of timed neuropsychological tests with the PATA rate and nine-hole pegboard tests 116
Dissociative Identity Disorder: Restoration of Executive Functions After Switch from Alter to Host Personality. 114
Friedreich ataxia: 150 years of bench and bedside studies 112
Totale 14.557
Salva come PNG Salva come JPEG
Categoria #
all - tutte 61.435
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 61.435
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022830 16 10 10 4 12 54 18 44 94 72 191 305
2022/20231.391 151 124 47 108 153 167 12 108 214 233 53 21
2023/2024934 30 125 108 51 44 100 5 150 12 22 198 89
2024/20255.061 210 221 37 82 166 247 665 318 302 488 1.894 431
2025/20269.947 1.037 817 1.045 961 1.648 431 1.155 602 1.067 671 295 218
2026/2027355 355 0 0 0 0 0 0 0 0 0 0 0
Totale 20.097